NEW YORK, Dec. 09, 2016 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Endo International plc (NASDAQ:ENDP) securities between September 28, 2015 and November 2, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/endo-international. There is no cost or obligation to you.
According to the complaint, during the Class Period, Defendants failed to disclose that: (i) Endo’s subsidiary, Par Pharmaceutical, had colluded with several of its industry peers to manipulate the prices of generic drugs; (ii) the foregoing conduct constituted a violation of federal antitrust laws; (iii) consequently, Endo’s revenues during the Class Period were in part the result of illegal conduct; and (iv) as a result of the foregoing, Endo’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Endo International you have until January 6, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/endo-international.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]


Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding?
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 



